ASIA BEAT: Getting used to bad news
This article was originally published in Scrip
Any outside observer scanning the pharma news flow from Asia over the past few weeks would be justified in concluding the sector to be characterized solely by broad corporate malfeasance or at least alleged wrongdoing in one form or another.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.